News & Views |
Featured
-
-
News & Views |
Tumours form without genetic mutations
Researchers find that brief and reversible inhibition of a gene-silencing mechanism leads to irreversible tumour formation in fruit flies, challenging the idea that cancer is caused only by permanent changes to DNA.
- Anne-Kathrin Classen
-
News |
Mini-colon and brain ‘organoids’ shed light on cancer and other diseases
Tiny 3D structures made from human stem cells sometimes offer insights that animal models cannot.
- Sara Reardon
-
Article
| Open AccessDiscovery of WRN inhibitor HRO761 with synthetic lethality in MSI cancers
HRO761 is a potent, selective, allosteric WRN inhibitor that binds at the interface of the D1 and D2 helicase domains, locking WRN in an inactive conformation.
- Stephane Ferretti
- , Jacques Hamon
- & Marta Cortés-Cros
-
Article
| Open AccessSpatiotemporally resolved colorectal oncogenesis in mini-colons ex vivo
Topobiologically complex mini-colons—which enable the faithful in vitro recapitulation of colorectal cancer tumorigenesis and its environmental determinants—offer the possibility to reduce animal use in a wide range of experimental applications.
- L. Francisco Lorenzo-Martín
- , Tania Hübscher
- & Matthias P. Lutolf
-
Article
| Open AccessPGE2 inhibits TIL expansion by disrupting IL-2 signalling and mitochondrial function
Prostaglandin E2 from the tumour microenvironment impairs interleukin-2 sensing by tumour-infiltrating lymphocytes, restricting proliferative response and promoting T cell death via metabolic impairment and ferroptosis.
- Matteo Morotti
- , Alizee J. Grimm
- & George Coukos
-
Article
| Open AccessPGE2 limits effector expansion of tumour-infiltrating stem-like CD8+ T cells
Tumour-derived prostaglandin E2, signaling through its receptors EP2 and EP4, is shown to restrain the responses of tumour-infiltrating stem-like TCF1+CD8+ T lymphocytes, and modulation of T cell EP2 and EP4 can restore anticancer immunity.
- Sebastian B. Lacher
- , Janina Dörr
- & Jan P. Böttcher
-
Article |
Chemoproteomic discovery of a covalent allosteric inhibitor of WRN helicase
VVD-133214, a clinical-stage, covalent allosteric inhibitor of the helicase WRN, was well tolerated in mice and led to robust tumour regression in multiple microsatellite-instability-high colorectal cancer cell lines and patient-derived xenograft models.
- Kristen A. Baltgalvis
- , Kelsey N. Lamb
- & Todd M. Kinsella
-
News |
AI traces mysterious metastatic cancers to their source
Algorithm examines images of metastatic cells to identify the location of the primary tumour.
- Smriti Mallapaty
-
Research Highlight |
Biological age surges in survivors of childhood cancer
People who survived paediatric cancers age faster and are at higher risk of early death.
-
News |
How to supercharge cancer-fighting cells: give them stem-cell skills
The bioengineered immune players called CAR T cells last longer and work better if pumped up with a large dose of a protein that makes them resemble stem cells.
- Sara Reardon
-
Article
| Open AccessFOXO1 is a master regulator of memory programming in CAR T cells
The transcription factor FOXO1 has a key role in human T cell memory, and manipulating FOXO1 expression could provide a way to enhance CAR T cell therapies by increasing CAR T cell persistence and antitumour activity.
- Alexander E. Doan
- , Katherine P. Mueller
- & Evan W. Weber
-
Article |
The PARTNER trial of neoadjuvant olaparib in triple-negative breast cancer
- Jean E. Abraham
- , Karen Pinilla
- & Helena M. Earl
-
Article
| Open AccessConcurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy
RMC-7977, a compound that exhibits potent inhibition of the active states of mutant and wild-type KRAS, NRAS and HRAS variants has a strong anti-tumour effect on RAS-addicted tumours and is well tolerated in preclinical models.
- Matthew Holderfield
- , Bianca J. Lee
- & Mallika Singh
-
Article |
Tumor-selective activity of RAS-GTP inhibition in pancreatic cancer
- Urszula N. Wasko
- , Jingjing Jiang
- & Kenneth P. Olive
-
Nature Podcast |
Audio long read: Why are so many young people getting cancer? What the data say
Researchers are scrambling to explain why rates of multiple cancers are increasing among adults under the age of 50.
- Heidi Ledford
- & Benjamin Thompson
-
Outline |
Video: Cancer-busting vaccines
Treatments that could train the immune system to identify and destroy cancer cells are on the way.
-
Outline |
Cancer-vaccine trials give reasons for optimism
Therapeutic vaccines could provide a transformative shot in the arm for cancer treatment.
- Liam Drew
-
Outline |
How does a cancer vaccine work?
After decades of slow progress, therapeutic vaccines that direct the immune system to attack tumours could soon become a fixture of cancer treatment.
- Liam Drew
-
Article |
TRBC1-targeting antibody–drug conjugates for the treatment of T cell cancers
Anti-TRBC1 antibody–drug conjugates may offer a more potent T cell cancer therapy by bypassing the fratricide that may be limiting the efficacy of anti-TRBC1 CAR T cells in the clinical trial for patients with T cell cancers.
- Tushar D. Nichakawade
- , Jiaxin Ge
- & Suman Paul
-
News |
How to make an old immune system young again
Antibodies that target blood stem cells can rejuvenate immune responses in mice.
- Heidi Ledford
-
Article |
Targeting DCAF5 suppresses SMARCB1-mutant cancer by stabilizing SWI/SNF
DCAF5 has a quality-control function for SWI/SNF complexes and promotes the degradation of incompletely assembled SWI/SNF complexes in the absence of SMARCB1.
- Sandi Radko-Juettner
- , Hong Yue
- & Charles W. M. Roberts
-
News |
Cutting-edge CAR-T cancer therapy is now made in India — at one-tenth the cost
The treatment, called NexCAR19, raises hopes that this transformative class of medicine will become more readily available in low- and middle-income countries.
- Smriti Mallapaty
-
Career Q&A |
‘Woah, this is affecting me’: why I’m fighting racial inequality in prostate-cancer research
Olugbenga Samuel Oyeniyi sought a career with a stronger public-health focus after learning that Black men are twice as likely as white men to get prostate cancer.
- Jacqui Thornton
-
News & Views |
Whittling down the bacterial subspecies that might drive colon cancer
Understanding the factors that drive formation of particular types of cancer can aid efforts to develop better diagnostics or treatments. The identification of a bacterial subspecies with a connection to colon cancer has clinical relevance.
- Cynthia L. Sears
- & Jessica Queen
-
Article
| Open AccessTranscription–replication conflicts underlie sensitivity to PARP inhibitors
Poly(ADP-ribose) polymerase 1 (PARP1) functions together with TIMELESS and TIPIN to protect the replisome in early S phase from transcription–replication conflicts, and inhibiting PARP1 enzymatic activity may suffice for treatment efficacy in homologous recombination-deficient settings.
- Michalis Petropoulos
- , Angeliki Karamichali
- & Thanos D. Halazonetis
-
Article
| Open AccessA distinct Fusobacterium nucleatum clade dominates the colorectal cancer niche
A study reveals that Fusobacterium nucleatum subspecies animalis is bifurcated into two distinct clades, and shows that only one of these dominates the colorectal cancer niche, probably through increased colonization of the human gastrointestinal tract.
- Martha Zepeda-Rivera
- , Samuel S. Minot
- & Christopher D. Johnston
-
Article
| Open AccessEvolutionary trajectories of small cell lung cancer under therapy
We uncover key processes of the genomic evolution of small cell lung cancer under therapy, identify the common ancestor as the source of clonal diversity at relapse and show central genomic patterns associated with drug response.
- Julie George
- , Lukas Maas
- & Roman K. Thomas
-
Obituary |
Anthony Epstein (1921–2024), discoverer of virus causing cancer in humans
Pathologist whose finding that viruses can trigger tumours in humans transformed medical research.
- Alan Rickinson
-
News Feature |
Why are so many young people getting cancer? What the data say
Clues to a modern mystery could be lurking in information collected generations ago.
- Heidi Ledford
-
News |
Deadly brain cancer shrinks after CAR-T therapy — but for how long is unclear
Early studies with engineered immune cells show drastic but often short-lived results in glioblastoma, the most aggressive brain cancer.
- Heidi Ledford
-
News Explainer |
First cell therapy for solid tumours heads to the clinic: what it means for cancer treatment
Therapy built on tumour-infiltrating lymphocytes is now being prepared for at least 20 people in the United States with advanced melanoma.
- Sara Reardon
-
Correspondence |
Personalized cancer care can’t rely on molecular testing alone
- James Larkin
- , Chloe Beland
- & Alexander R. Lyon
-
Correspondence |
Forget lung, breast or prostate cancer? Why we shouldn’t abandon tumour names yet
- Albrecht Stenzinger
- & Frederick Klauschen
-
Spotlight |
Stealthy stem cells to treat disease
Gene-editing strategies that allow stem cells to evade the immune system offer hope for universal cell-replacement therapies.
- Elie Dolgin
-
Article
| Open AccessAn atlas of epithelial cell states and plasticity in lung adenocarcinoma
Analyses of single epithelial cells from early-stage lung adenocarcinoma and normal lung identifies a population of intermediate cells that may have an increased likelihood of transforming to tumour cells after injury such as tobacco exposure.
- Guangchun Han
- , Ansam Sinjab
- & Humam Kadara
-
Article |
SOX17 enables immune evasion of early colorectal adenomas and cancers
Transcriptomic and chromatin accessibility analyses of naive and transplanted colon cancer organoids in a mouse model reveal a key role for the transcription factor SOX17 in establishing a permissive immune environment for tumour cells.
- Norihiro Goto
- , Peter M. K. Westcott
- & Ömer H. Yilmaz
-
Article |
Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells
A high baseline of intratumoural macrophages and regulatory T cells is associated with better outcomes in patients with non-small cell lung cancer treated with atezolizumab plus tiragolumab, but not with atezolizumab alone.
- Xiangnan Guan
- , Ruozhen Hu
- & Namrata S. Patil
-
Obituary |
Judith Campisi (1948–2024), cell biologist who explored how cells age
Researcher who established the role of cellular senescence in cancer and ageing.
- Jan Vijg
- & Jan Hoeijmakers
-
News |
MEGA-CRISPR tool gives a power boost to cancer-fighting cells
A system that edits RNA rather than DNA can give new life to exhausted CAR T cells.
- Sara Reardon
-
Review Article |
Natural killer cell therapies
This Review explores in detail the complexity of NK cell biology in humans and highlights the role of these cells in cancer immunity.
- Eric Vivier
- , Lucas Rebuffet
- & Valeria R. Fantin
-
Article
| Open AccessMechanisms of action and resistance in histone methylation-targeted therapy
The mechanisms of action and resistance of valemetostat, an EZH1–EZH2 dual inhibitor, in patients with adult T cell leukaemia/lymphoma who initially responded but later showed disease progression are explored.
- Makoto Yamagishi
- , Yuta Kuze
- & Kaoru Uchimaru
-
Technology Feature |
Super-speedy sequencing puts genomic diagnosis in the fast lane
Streamlined workflows for DNA and RNA sequencing are helping clinicians to deliver prompt, targeted care to people in days — or even hours.
- Michael Eisenstein
-
News Feature |
The future of precision cancer therapy might be to try everything
Researchers are blasting patients’ cancer cells with dozens of drugs in the hope of finding the right treatment.
- Elie Dolgin
-
Article |
Deep whole-genome analysis of 494 hepatocellular carcinomas
The Chinese Liver Cancer Atlas project depicts a panoramic genomic landscape of hepatocellular carcinoma, covering candidate coding and non-coding drivers, mutational signatures, extrachromosomal circular DNA, subclonal catastrophic events and detailed evolutionary history.
- Lei Chen
- , Chong Zhang
- & Hongyang Wang
-
Article
| Open AccessGenetic determinants of micronucleus formation in vivo
Genetic screening identifies a rich catalogue of regulators of micronucleus formation.
- D. J. Adams
- , B. Barlas
- & G. Balmus
-
Nature Podcast |
Why we need to rethink how we talk about cancer
Naming metastatic cancers after parts of the body could be holding up research and preventing people from accessing the best treatment
- Lucy Odling-Smee
- & Noah Baker
-
News |
Turbocharged CAR-T cells melt tumours in mice — using a trick from cancer cells
Immune cells armed with a mutation first identified in cancer cells gain potency but don’t turn cancerous themselves.
- Asher Mullard
-
Article |
Naturally occurring T cell mutations enhance engineered T cell therapies
A study examines the effects of mutations that occur naturally in T cell cancers, reporting that such mutations can potentially be exploited to increase the potency of T cell therapies.
- Julie Garcia
- , Jay Daniels
- & Jaehyuk Choi
-
Article
| Open AccessThe nuclear factor ID3 endows macrophages with a potent anti-tumour activity
The Kupffer cell lineage-determining factor ID3 selectively endows macrophages with the ability to phagocytose live tumour cells and orchestrate the recruitment, proliferation and activation of natural killer and CD8+ T lymphoid effector cells to restrict the growth of a variety of tumours.
- Zihou Deng
- , Pierre-Louis Loyher
- & Frederic Geissmann
Browse broader subjects
Browse narrower subjects
- Bone cancer
- Breast cancer
- Cancer epidemiology
- Cancer genetics
- Cancer genomics
- Cancer imaging
- Cancer metabolism
- Cancer microenvironment
- Cancer models
- Cancer of unknown primary
- Cancer prevention
- Cancer screening
- Cancer stem cells
- Cancer therapy
- CNS cancer
- Cysts
- Embryonal neoplasms
- Endocrine cancer
- Eye cancer
- Gastrointestinal cancer
- Germ cell tumours
- Gynaecological cancer
- Haematological cancer
- Hamartoma
- Head and neck cancer
- Lung cancer
- Mesothelioma
- Metastasis
- Oncogenes
- Oral cancer
- Paediatric cancer
- Sarcoma
- Skin cancer
- Testicular cancer
- Tumour angiogenesis
- Tumour biomarkers
- Tumour heterogeneity
- Tumour immunology
- Tumour-suppressor proteins
- Tumour virus infections
- Urological cancer